EGFR and non-small cell lung carcinoma: In large retrospective cohorts already published, patients with uncommon EGFR mutated NSCLC presented significantly lower mPFS (from 3 to 9 months) compared to patients with exon 19 and 21 mutations [27,28,29,30].